Lectenz Bio receives NIH NIGMS SBIR Phase I

Lectenz Bio receives NIH NIGMS SBIR Phase I

The NIH National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase I to develop fucose binding Lectenz®.